Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will present ...

The Paris AI Action Summit, under the banner of ethical AI innovation, appears disconnected from the realities of how ...

Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") , which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Q4 2024 Management View CEO Reshma Kewalramani highlighted the planned leadership transitions, with Stuart Arbuckle retiring in July 2025. Charlie Wagner will take on additional responsibilities as ...

Our concern this week is that any positive news on inflation will be drowned out by tariff news. As with stocks, future ...

In a world where concrete is as ubiquitous as air, its environmental toll is impossible to ignore. The production of cement, ...

A group of former Allen Institute for AI research leaders have formed a new Seattle-based artificial intelligence startup, Vercept.